Lynch syndrome in colorectal cancer patients

References

• Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N. Engl. J. Med.348, 919–932 (2003).
   PubMed Web of Science ®Google Scholar
• Piñol V, Andreu M, Castells A et al. Frequency of hereditary non-polyposis colorectal cancer and other colorectal cancer familial forms in Spain. A multicenter, prospective, nation-wide study. Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Eur. J. Gastroenterol. Hepatol.16, 39–45 (2004).
   PubMedGoogle Scholar
• Kraus C, Kastl S, Gunther K et al. A proven de novo germline mutation in HNPCC. J. Med. Genet.36, 919–921 (1999).
   PubMedGoogle Scholar
• Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer71, 677–685 (1993).
   PubMed Web of Science ®Google Scholar
• Stoffel E, Kastrinos F, Balmaña J et al. Comparison of phenotype by mismatch repair gene mutation among probands undergoing clinical genetic testing for MLH1 and MSH2. Gastroenterology132, 391 (2007).
   Google Scholar
• Fishel R, Lescoe MK, Rao MR et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell75, 1027–1038 (1993).
   PubMed Web of Science ®Google Scholar
• Bronner CE, Baker SM, Morrison PT et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature368, 258–261 (1994).
   PubMed Web of Science ®Google Scholar
• Peltomaki P, Vasen HF. Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology113, 1146–1158 (1997).
   PubMed Web of Science ®Google Scholar
• Felton KE, Gilchrist DM, Andrew SE. Constitutive deficiency in DNA mismatch repair. Clin. Genet.71, 483–498 (2007).
   PubMed Web of Science ®Google Scholar
• Vasen HF, Möslein G, Alonso A et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J. Med. Genet.44, 353–362 (2007).
   PubMed Web of Science ®Google Scholar
• Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis. Colon Rectum34, 424–425 (1991).
   PubMed Web of Science ®Google Scholar
• Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology116, 1453–1456 (1999).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bigas MA, Boland CR, Hamilton SR et al. A National Cancer Institute workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda guidelines. J. Natl Cancer Inst.89, 1758–1762 (1997).
   PubMedGoogle Scholar
• Umar A, Boland CR, Terdiman JP et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J. Natl Cancer Inst.96, 261–268 (2004).
   PubMed Web of Science ®Google Scholar
• Piñol V, Castells A, Andreu M et al. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA293, 1986–1994 (2005).
   PubMedGoogle Scholar
• Hampel H, Frankel WL, Martin E et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N. Engl. J. Med.352, 1851–1860 (2005).
   PubMed Web of Science ®Google Scholar
• Rodríguez-Moranta F, Castells A, Andreu M et al. Clinical performance of original and revised Bethesda guidelines for the identification of MSH2/MLH1 gene carriers in patients with newly diagnosed colorectal cancer: proposal of a new and simpler set of recommendations. Am. J. Gastroenterol.101, 1104–1111 (2006).
   PubMedGoogle Scholar
• Giardiello FM, Brensinger JD, Petersen GM. AGA technical review on hereditary colorectal cancer and genetic testing. Gastroenterology121, 198–213 (2001).
   PubMed Web of Science ®Google Scholar
• Aaltonen LA, Salovaara R, Kristo P et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N. Engl. J. Med.338, 1481–1487 (1998).
   PubMed Web of Science ®Google Scholar
• Salovaara R, Loukola A, Kristo P et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J. Clin. Oncol.18, 2193–2200 (2000).
   PubMed Web of Science ®Google Scholar
• Boland CR, Thibodeau SN, Hamilton SR et al. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res.58, 5248–5257 (1998).
   PubMed Web of Science ®Google Scholar
• Zhou XP, Hoang JM, Li YJ et al. Determination of the replication error phenotype in human tumors without the requirement for matching normal DNA by analysis of mononucleotide repeat microsatellites. Genes Chromosomes Cancer21, 101–107 (1998).
   PubMedGoogle Scholar
• Suraweera N, Duval A, Reperant M et al. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology123, 1804–1811 (2002).
   PubMed Web of Science ®Google Scholar
• Xicola RM, Llor X, Pons E et al. Performance of different microsatellite marker panels for detection of mismatch repair-deficient colorectal tumors. J. Natl Cancer Inst.99, 244–252 (2007).
   PubMed Web of Science ®Google Scholar
• Michael-Robinson JM, Biemer-Huttmann A, Purdie DM et al. Tumour infiltrating lymphocytes and apoptosis are independent features in colorectal cancer stratified according to microsatellite instability status. Gut48, 360–366 (2001).
   PubMed Web of Science ®Google Scholar
• Kohonen-Corish MR, Daniel JJ, Chan C et al. Low microsatellite instability is associated with poor prognosis in stage C colon cancer. J. Clin. Oncol.23, 2318–2324 (2005).
   PubMedGoogle Scholar
• Wright CM, Dent OF, Newland RC et al. Low level microsatellite instability may be associated with reduced cancer specific survival in sporadic stage C colorectal carcinoma. Gut54, 103–108 (2005).
   PubMedGoogle Scholar
• Kane MF, Loda M, Gaida GM et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res.57, 808–811 (1997).
   PubMed Web of Science ®Google Scholar
• Bessa X, Ballesté B, Andreu M et al. BRAF mutational analysis improves efficacy and efficiency of Lynch syndrome screening: a prospective, multicenter, population-based study. Clin. Gastroenterol. Hepatol.6, 206–214 (2008).
   PubMed Web of Science ®Google Scholar
• Deng G, Bell I, Crawley S et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not inhereditary nonpolyposis colorectal cancer. Clin. Cancer Res.10, 191–195 (2004).
   PubMed Web of Science ®Google Scholar
• Benlloch S, Paya A, Alenda C et al. Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodology. J. Mol. Diagn.8, 540–543 (2006).
   PubMedGoogle Scholar
• Dietmaier W, Wallinger S, Bocker T, Kullmann F, Fishel R, Ruschoff J. Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res.57, 4749–4756 (1997).
   PubMed Web of Science ®Google Scholar
• Wijnen JT, Vasen HF, Khan PM et al. Clinical finding with implications for genetic testing in families with clustering of colorectal cancer. N. Engl. J. Med.339, 511–518 (1998).
   PubMedGoogle Scholar
• Barnetson RA, Tenesa A, Farrington SM et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N. Engl. J. Med.354, 2751–2763 (2006).
   PubMed Web of Science ®Google Scholar
• Chen S, Wang W, Lee S et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA296, 1479–1487 (2006).
   PubMed Web of Science ®Google Scholar
• Balmaña J, Stockwell DH, Steyerberg EW et al. Prediction of MLH1 and MSH2 mutations in Lynch syndrome. JAMA296, 1469–1478 (2006).
   PubMedGoogle Scholar
• Balaguer F, Balmaña J, Castellví-Bel S et al. Validation and extension of the PREMM1,2 model in a population-based cohort of colorectal cancer patients. Gastroenterology134(1), 39–46 (2008).
   PubMedGoogle Scholar
• Taylor CF, Charlton RS, Burn J, Sheridan E, Taylor GR. Genomic deletions in MSH2 or MLH1 are a frequent cause of hereditary non-polyposis colorectal cancer: identification of novel and recurrent deletions by MLPA, Hum. Mutat.22, 428–433 (2003).
   PubMed Web of Science ®Google Scholar
• Castellvi-Bel S, Castells A, Strunk M et al. Genomic rearrangements in MSH2 and MLH1 are rare mutational events in Spanish patients with hereditary nonpolyposis colorectal cancer. Cancer Lett.225, 93–98 (2005).
   PubMed Web of Science ®Google Scholar
• American Gastroenterological Association. AGA medical position statement: hereditary colorectal cancer and genetic testing. Gastroenterology121, 195–197 (2001).
   PubMed Web of Science ®Google Scholar
• Giardiello FM, Brensinger JD, Petersen GM. AGA technical review on hereditary colorectal cancer and genetic testing. Gastroenterology121, 198–213 (2001).
   PubMed Web of Science ®Google Scholar
• Winawer S, Fletcher R, Rex D et al. Gastrointestinal Consortium Panel. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology124, 544–560 (2003).
   PubMed Web of Science ®Google Scholar
• Järvinen HJ, Aarnio M, Mustonen H et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology118, 829–834 (2000).
   PubMed Web of Science ®Google Scholar
• de Vos tot Nederveen Cappel WH, Nagengast FM, Griffioen G et al. Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. Dis. Colon Rectum45, 1588–1594 (2002).
   PubMed Web of Science ®Google Scholar
• de Vos tot Nederveen Cappel WH, Buskens E, van Duijvendijk P et al. Decision analysis in the surgical treatment of colorectal cancer due to a mismatch repair gene defect. Gut52, 1752–1755 (2003).
   PubMed Web of Science ®Google Scholar
• Carethers JM, Chauhan DP, Fink D et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology117, 123–131 (1999).
   PubMed Web of Science ®Google Scholar
• Carethers JM, Smith EJ, Behling CA et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology126, 394–401 (2004).
   PubMed Web of Science ®Google Scholar
• de Vos tot Nederveen Cappel WH, Meulenbeld HJ, Kleibeuker JH et al. Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. Int. J. Cancer109, 468–471 (2004).
   PubMedGoogle Scholar
• Liang JT, Huang KC, Lai HS et al. High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection. Int. J. Cancer101, 519–525 (2002).
   PubMedGoogle Scholar
• Ribic CM, Sargent DJ, Moore MJ et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil based adjuvant chemotherapy for colon cancer. N. Engl. J. Med.349, 247–257 (2003).
   PubMed Web of Science ®Google Scholar
• Jover R, Zapater P, Castells A et al. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut55, 848–855 (2006).
   PubMed Web of Science ®Google Scholar
• Fallik D, Borrini F, Boige V et al. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res.63, 5738–5744 (2003).
   PubMed Web of Science ®Google Scholar
• Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J. Clin. Oncol.23, 2840–2855 (2005).
   PubMed Web of Science ®Google Scholar
• Garcia-Rodriguez LA, Huerta-Alvarez C. Reduced risk of colorectal cancer among long-term users of aspirin and non-aspirin non-steroidal anti-inflammatory drugs. Epidemiology12, 88–93 (2001).
   PubMed Web of Science ®Google Scholar
• Baron JA, Cole BF, Sandler RS et al. A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med.348, 891–899 (2003).
   PubMed Web of Science ®Google Scholar
• Karnes WE Jr, Shattuck-Brandt R, Burgart LJ et al. Reduced COX-2 protein in colorectal cancer with defective mismatch repair. Cancer Res.58, 5473–5477 (1998).
   PubMedGoogle Scholar
• Castells A, Paya A, Alenda C et al. Cyclooxygenase 2 expression in colorectal cancer with DNA mismatch repair deficiency. Clin. Cancer Res.12, 1686–1692 (2006).
   PubMedGoogle Scholar